

eISSN: 2582-8185 Cross Ref DOI: 10.30574/ijsra Journal homepage: https://ijsra.net/



(RESEARCH ARTICLE)

Check for updates

Profile of women with Gynaecological cancers at a Tertiary Hospital in Southern Nigeria

Justina Omoikhefe Alegbeleye * and Celestine Osita John

Department of Obstetrics and Gynaecology, University of Port Harcourt Teaching Hospital, Rivers state, Nigeria.

International Journal of Science and Research Archive, 2024, 11(02), 238–246

Publication history: Received on 28 January 2024; revised on 04 March 2024; accepted on 07 March 2024

Article DOI: https://doi.org/10.30574/ijsra.2024.11.2.0409

Abstract

Background: Gynaecological cancers remain a major public health concern in Low-and Middle-Income Countries. In sub-Saharan Africa, gynaecological cancers account for approximately one-third of all female cancers.

Objectives: To determine the socio-demographic, reproductive, and clinical characteristics of gynaecological cancer patients at the University of Port Harcourt Teaching Hospital.

Materials and Methods: This was a prospective cross-sectional study of 75 women with histologically confirmed gynaecological cancer managed at the University of Port Harcourt Teaching Hospital, from January 1, 2022, to December 31, 2022. A structured interviewer-administered questionnaire was used to obtain socio-demographic characteristics and clinical profile from the patients and their clinical records after informed consent was obtained. Data was entered into a MS Excel spreadsheet and analyzed with SPSS version 25.

Results: Most 27 (36%) of the women were between 40-49 years of age, with a mean age of 50.4 ± 12.3 years. Majority 46 (61.3%) were married, 27 (36%) had tertiary education, and two-thirds earned N30,000 or less (\leq \$20) per month. Many 23 (30.7%) were Para \geq 5, almost all 63 (84%) of the women were referred to UPTH, with one-third 21 (33.3%) of the referrals coming from other tertiary health facilities. Most 63 (84%) of the women had never had a Pap smear screening, and 48 (64%) were menopausal. The most common presenting symptom was vaginal bleeding 37 (49.3%). Cervical cancer accounted for about half 40 (53.3%) of the cases, followed by ovarian cancer 27 (36%), with the majority 28 (43%) presenting with stage III disease. Chemotherapy was administered to all the patients. However, treatment was delayed in 57 (76%) of the women due to financial constraints, with most of the funding and support coming from family members in 43 (57.3%) of the women.

Conclusion: There is an urgent need to increase advocacy for gynaecological cancers to increase awareness, prevent late presentation and progression of early disease. Furthermore, the government needs to subsidize the cost of cancer care to encourage early presentation and treatment.

Keywords: Gynaecological Cancer; Demography; Clinical profile; Nigeria

1. Introduction

Gynaecological cancers are malignancies of the genital tract which involves the cervix, ovary, uterus, vulva, vagina, and gestational trophoblastic neoplasia (GTN) [1]. These malignancies have different epidemiology, pathology, and management interventions [2]. Though cancers of the uterus, cervix, vagina, vulva, ovary, choriocarcinoma and fallopian tubes are managed by the gynaecologists, breast cancer is mostly managed by general surgeons in many developing countries, Nigeria inclusive [3].

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

^{*} Corresponding author: Alegbeleye, Justina Omoikhefe; ORCID ID: 0000-0003-1608-888X

The global cancer data reveal that the burden has risen to 18 million cases and 9.6 million deaths annually, with over 50% of the new cancer incidences recorded in Asia [4]. Gynaecological cancers remain a crucial public health menace worldwide, as it is among the leading causes of morbidity in women and cancer-associated mortalities globally [2]. Aside breast cancer, gynaecological cancers are the second most common cancers, accounting for over 17% of all types of cancers in women [5].

The epidemiology of these gynaecological cancers varies across different countries, due to genetic traits, lifestyle, and socio-economic factors [6]. In developed countries, gynaecological cancers constitute about 16% of all cancers, while they account for 25% in developing nations [1]. Globally, the most common gynaecological cancer is cervical cancer with a prevalence of about 13%, while those of endometrial, ovarian and vulva cancers are 8%, 6% and 0.9% respectively [7]. Similarly, the most common types of gynaecological cancer in the African region are cervical, ovarian, and uterine cancers [8,9]. Although, no national comprehensive data exist for the prevalence of these gynaecological cancers in Nigeria, however several studies have been conducted in various parts of the country to evaluate the burden of these cancers in the general population. Cervical cancers have a high prevalence in Nigeria which could be attributed to the lack of awareness, lack of political will, poor infrastructure, and almost non-existent cervical screening programmes [10-12]. Reported prevalence of cervical cancer in Nigeria include 60% at Ebonyi [10], 66% at Enugu [13], 69% at Sokoto [14], 74% at Jos [15], while 73% and 74% were reported at Oyo and Edo respectively [13].

Ovarian cancers are the second highest cause of mortalities in patients with gynaecological cancers [8]. It is estimated that about 75% of the patients present late with advanced stages of this cancer because of its nonspecific symptoms [16]. It accounted for 19% and 28% incidence for studies conducted at Ebonyi and Abuja respectively [10,16]. Moreover, the high mortality associated with ovarian cancers is due to late presentation, as it has no premalignant stage and there are no specific screening tests [13,17].

Factors such as age and parity have been identified as some of the major risk factors for gynaecological cancers. Endometrial and ovarian cancers are more common in older women, while choriocarcinoma occur in the younger age group [2,8]. Although multiparity has been reported as a protective factor against endometrial and ovarian cancers, it is a major risk factor for cervical cancer [2]. Hence, the study sought to determine the socio-demographic, reproductive, and clinical profile of gynaecological cancer patients at the University of Port Harcourt Teaching Hospital in River state, Nigeria.

2. Materials and Methods

2.1. Study Area

This study was conducted at the gynaecological oncology unit of the University of Port Harcourt Teaching Hospital (UPTH). The University of Port Harcourt Teaching Hospital is a 988-bed hospital in Alakahia, in Obio-Akpor Local Government Area of Rivers state. It is a tertiary hospital that serves as a referral centre for all levels of healthcare in Rivers state and other neighbouring states including Bayelsa, Imo and Abia. Every week, the gynaecological oncology runs on Friday, and each clinic session is led by a team of consultants. Patients are evaluated in the clinic before they are admitted into the gynaecological ward for surgery.

2.2. Methods

This was a prospective cross-sectional study of 75 women with histologically confirmed gynaecological cancer managed at the University of Port Harcourt Teaching Hospital between January 1, 2022, and December 31, 2022. Women who refused consent and very ill patients were excluded from the study. The purpose of the study was duly explained to the women and informed consent forms were signed by the participants. A structured interviewer-administered questionnaire designed for this purpose was used to obtain socio-demographic and clinical parameters. Each participant was assigned a unique identity to ensure anonymity and ease of identification. The data collection tools were checked daily for accuracy and completeness.

2.3. Data Analysis

The data collected was entered into an MS Excel spreadsheet. The data was cleaned and analyzed using Statistical Package for Social Sciences (SPSS) version 25. The socio-demographic characteristics and clinical information were summarized using descriptive statistics (mean, frequency percentage and standard deviation) as appropriate.

2.4. Ethical Considerations

Ethical approval for the study was obtained from the Ethics and Research Committee of the University of Port Harcourt Teaching Hospital. Personal identifying information was kept confidential.

3. Results

The table 1 showed that 27 (36.0%) of the respondents were in 40-49 years age group, 46 (61.3%) were married, 27 (36.0%) had tertiary education and 45 (60.0%) of the respondents were businesswomen. The mean age of the respondents was 50.4 ± 12.3 years. About two-thirds, 55 (73.3%) of the respondents were active with 45 (60.0%) earning N30,000 or below (\leq \$20) monthly. This is shown in Table 1.

The table 2 showed that most 34 (45.3%) of the women were Para 2 or less, and 37 (49.3%) had one or two living children. Of the 75 patients, 63 (84.0%) were referred, with 21 (33.3%) of them referred from other tertiary health facilities, 19 (30.2%) were referred from general hospitals and 16 (25.4%) were referred from private facilities. Table 3 showed that 34 (45.3%) of the respondents attained menarche between 13-14 years, 37 (49.3%) had coitarche at more than 18 years, only 9 (12.0%) had Pap smear screening, 12 (16.0%) had used hormonal contraceptive, and 48 (64.0%) were menopausal.

The clinical characteristics of the patients are presented in table 4. About half 40 (53.3%) of the women had cervical cancer, while 27 (36.0%) had ovarian cancer. Most of the women presented with vaginal bleeding 37 (49.3%) and abdominal swelling 36 (48.0%), with majority presenting in stage III 32 (42.7%) and IV 24 (32%) disease. Furthermore, 38 (50.7%) were diagnosed within 1 year, and 36 (48.0%) had undergone total abdominal hysterectomy, bilateral salpingo-ovariectomy, infracolic omentectomy, and pelvic lymph node dissection. Disease recurrence was observed in 11 (14.7%) patients.

Table 5 showed that 43 (57.3%) of the respondents have support from family members, 40 (53.3%) from spouse, and 34 (45.3%) from their children. Moreover, 50 (66.7%) have financial support from their family, 35 (46.7%) from their spouse, and 16 (21.3%) were self-funded.

A quarter 20 (26.7%) of the women had chronic hypertension, while only 6 (8.0%) had diabetes mellitus. This is shown in Table 6. Of the 75 respondents, 4 (80.0%) reported a family history of breast cancer, with only 1 (20%) having a family history of ovarian cancer.

Variable	Frequency n=75	Percent (%)
Age group (years)		
<20	2	2.7
20-29	3	4.0
30-39	6	8.0
40-49	27	36.0
50-59	22	29.3
60-69	15	20.0
Mean ± SD	50.4±12.3	
Marital status		
Single	9	12.0
Married	46	61.3
Divorced	2	2.7
Separated	6	8.0
Cohabiting	12	16.0

Table 1 Socio-Demographic Characteristics

Education		
None	5	6.7
Primary	25	33.3
Secondary	16	21.3
Intermediate	2	2.7
Tertiary	27	36.0
Occupation		
Business	45	60.0
Farming	8	10.7
Artisan	7	9.3
Teaching	7	9.3
Unemployed	5	6.7
Others	3	4.0
Occupation status		
Active	55	73.3
Inactive	16	21.3
Retired	4	5.3
Monthly income(naira)		
≤30000	45	60.0
30001 - 60000	10	13.3
60001 - 90000	4	5.3
90000 -120000	10	13.3
>120000	6	8.0

Table 2 Obstetric History

Variable	Frequency	Percent (%)
Parity		
≤2	34	45.3
3-4	18	24.0
≥5	23	30.7
No of Living Children		
≤2	37	49.3
3-4	21	28.0
≥5	17	22.7
Patient referred		
Yes	63	84.0
No	12	16.0

Source of referral		
Tertiary Health Centre	21	33.3
General Hospital	19	30.2
Private Clinic/ Maternity	16	25.4
Primary Health Centre	6	9.5
Others	1	1.6

Table 3 Gynaecological History

Variable	Frequency n=75	Percent (%)
Age at menarche		
10-12	30	40.0
13-14	34	45.3
>14	11	14.7
Age at coitarche		
13-15	17	22.7
16-18	21	28.0
>18	37	49.3
Pap Smear Screening		
Yes	9	12.0
No	66	88.0
Hormonal contraceptive		
Yes	12	16.0
No	63	84.0
Type of hormonal contraceptive (n=12)		
Oral contraceptive	7	58.3
Injectables	5	41.7
Menopausal		
Yes	48	64.0
No	27	36.0

Table 4 Clinical Characteristics

Variable	Frequency n=75	Percent (%)
Type of Cancer		
Cervical	40	53.3
Ovarian	27	36.0
Endometrial	6	8.0

Vulvar	2	2.7
Presenting symptoms*		
Vaginal bleeding	37	49.3
Abdominal swelling	36	48.0
Abdominal pains	17	22.7
Weight loss	14	18.7
Stage of disease		
Stage 1	3	4.0
Stage 2	16	21.3
Stage 3	32	42.7
Stage 4	24	32.0
Duration of diagnosis		
< 1 year	38	50.7
1-2 years	36	48.0
≥ 3 years	1	1.3
Type of treatment		
Type of treatment Chemotherapy	35	46.7
Type of treatment Chemotherapy Surgery	35 36	46.7 48.0
Type of treatmentChemotherapySurgeryBoth	35 36 4	46.7 48.0 5.3
Type of treatmentChemotherapySurgeryBothDisease Recurrence	35 36 4	46.7 48.0 5.3
Type of treatmentChemotherapySurgeryBothDisease RecurrenceYes	35 36 4 11	46.7 48.0 5.3 14.7

*Multiple responses apply

Table 5 Funding and Support

Variable	Frequency n=75	Percent (%)
Type of support*		
Family	43	57.3
Spouse	40	53.3
Children	34	45.3
Friends and colleagues	6	8.0
Health personal	3	4.0
Source of funds*		
Family	50	66.7
Spouse	35	46.7
Self	16	21.3
Friends/colleagues	6	8.0

*Multiple responses apply

Table 6 Medical History

Variable	Frequency n=75	Percent (%)
Hypertensive		
Yes	20	26.7
No	55	73.3
Diabetes mellitus		
Yes	6	8.0
No	69	92.0
Hyperlipidaemia		
Yes	2	2.7
No	73	97.3

Table 7 Family and Social History

Variable	Frequency n=75	Percent (%)
Family history of cancer		
Yes	5	6.7
No	70	93.3
Type of cancer in family member		
Breast cancer	4	80.0
Ovarian cancer	1	20.0
Alcohol Use		
Yes	13	17.3
No	62	82.7
Tobacco Use		
Yes	1	1.3
No	74	98.7

4. Discussion

Gynaecological cancers remain a huge burden in Nigeria, despite it being on a downward trend in developed countries. In this study, cervical cancer was the most common gynaecological cancer, followed by ovarian cancer. This high prevalence could be attributed to the lack of cervical cancer awareness and organized screening programmes with respect to cervical cancer, and non-specific symptoms in women with ovarian cancer, hence the late presentation [16]. This is consistent with previous findings of Joseph et al [10], Okeke et al [13], Ibrahim and Ijaiya [18], Umeobika et al [19], and Osinachi et al [20], who all reported cervical and ovarian cancers as the most common gynaecological cancers in the various studies across Nigeria. Similarly, Birara et al, and Afroz et al reported the same pattern of gynaecological cancers in Ethiopia and Bangladesh respectively [1,21].

Age as a demographic factor has been implicated as one of the risk factors for gynaecological cancers. In this study, gynaecological cancers were most prevalent in the 40-49 years age group. This correlated with the findings of Umeobika et al [19], among gynaecological cancer patients in Imo State, Nigeria. In addition, the mean age in our study was 50.4 ± 12.3 years, which further shows that gynaecological cancers are more prevalent in women in the fourth and fifth decades of life. This finding corroborates the report of Abdullahi and Ayogu [16] who reported a mean age of 51.16

years at a study in Abuja, Nigeria. However, it was at variance with observations made by Joseph et al [10] and Nnadi et al [14] who reported a slightly higher mean age of 54 years respectively. This further emphasizes that gynaecological cancers are more common in the fifth decade of life.

Other demographic factors are marital status, level of education, employment, and income. The relationship between these factors and gynaecological cancers have not been widely reported in Nigeria. However, Sharma and Pattanshetty [22] in an Indian study reported that married women were more susceptible to cervical cancer, whereas Garg and Dasari [23] reported that lower socio-economic status was the dominant risk factor among gynaecological cancer patients in India.

Concerning the reproductive characteristics, the study showed that gynaecological cancers were more common in women with low parity, who were menopausal. Surprisingly, most of them had never had a pap smear screening. Of these, the most widely documented is the relationship between parity and gynaecological cancers. In contrast, Joseph et al [10], Abdulrahim and Ayogu [16], Ibrahim and Ijaiya [18], Osinachi et al [20], all reported in their respective studies across Nigeria that gynaecological cancers were more common in women with high parity among gynaecological cancer patients.

The most frequent presenting complaints among the women were vaginal bleeding and abdominal swelling. Furthermore, 26% were hypertensive, 8% were diabetic, 6% had a family history of cancer, 17% took alcohol, while only 1.3% tobacco usage. Although, the relationship between these factors and gynaecological cancers have not been widely studied in Nigeria, this result is lower than the findings of Wasim et al [6], who reported 48% hypertension, 42% diabetes, 8% family history of cancer and 29% tobacco usage, among gynaecological cancer patients in Pakistan. Moreover, the reason for these low results could be attributed to differences in lifestyle, social habits and effective prevention of diabetes mellitus, and hypertension among the study population.

5. Conclusion

Gynaecological cancer especially cervical and ovarian cancers are still prevalent in our environment. There is an urgent need to increase advocacy for gynaecological cancers to increase awareness, prevent late presentation and progression of early disease. Furthermore, the government needs to subsidize the cost of cancer care to enable early treatment.

Compliance with ethical standards

Acknowledgments

The authors acknowledge all the women who gave consent to participate in the study.

Disclosure of conflict of interest

The authors have declared that no conflicts of interests exist.

Statement of ethical approval

Ethical approval for the study was obtained from the Ethics and Research Committee of the University of Port Harcourt Teaching Hospital.

Statement of informed consent

Informed consent was obtained from all individual participants included in the study.

References

- [1] Birara M, Urgie T, Sium AF. Profile Of Gynecololgic Cancers at A Tertiary Hospital Addis Ababa, Ethiopia: A 4-Year Review. Ethiopian J Reprod Health 2024; 16:44-51.
- [2] Awoyesuku PA, Kwosah NJ, John DH, Amadi SC. Hysterectomy for primary gynaecological malignancies in a noncancer centre: prevalence, indications, and surgical outcomes at a tertiary hospital in Port-Harcourt, Nigeria: a six-year review. Int J Reprod Contracept Obstet Gynecol 2021; 10:4052-4058

- [3] Iyoke CA, Ugwu GO. Burden of gynaecological cancers in developing countries. World J Obstet Gynecol 2013;2(1):1-7.
- [4] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
- [5] Basile S, Angioli R, Manci N, Palaia I, Plotti F, Benedetti PP. Gynecological cancers in developing countries: the challenge of chemotherapy in low resource setting. Int J Gynecol Cancer. 2006;16 (4):1491-1497.
- [6] Wasim T, Mushtaq J, Wasim AZ, Gul-e-Raana. Gynecological malignancies at tertiary care hospital, Pakistan: A five-year review. Pak J Med Sci. 2021;37(3):621-627.
- [7] Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.
- [8] Yakasai IA, Ugwa EA, Otubu J. Gynecological malignancies in Aminu Kano teaching hospital Kano: A 3-year review. Niger J Clin Pract 2013; 16:63-66.
- [9] Lorenzoni, C, Vilajeliu A, Carrilho C, Castillo P, Barreales S, Ismail MR et al. Gynaecological malignancies at a tertiary care centre in Mozambique. European Journal of Gynaecological Oncology, 2019; 40 (2):295-299.
- [10] Joseph A, Oliaemeka EP, Chukwudi OR, Igwe NM, Agwu MR, Egbuji CC. Frequency, and pattern of gynecological cancers in federal teaching hospital, Abakaliki, Nigeria. J Basic Clin Reprod Sci 2015; 2:54-57.
- [11] Iyoke CA, Ugwu G, Ezugwu EC, Ezeugwu FO, Lawal OL, Onyebuchi AZ. Challenges associated with the management of gynecological cancers in a tertiary hospital in Southeast Nigeria. Int J Women's Health 2014; 6:123-30.
- [12] Elisabete W, France L. Malignant tumors of the female reproductive system. Saf Health Work 2012; 3:166-180.
- [13] Okeke TC, Onah N, Ikeako LC, Ezenyeaku C. The frequency and pattern of female genital tract malignancies at the University of Nigeria teaching hospital, Enugu, Nigeria. Ann Med Health Sci Res 2013; 3:345-348.
- [14] Nnadi DC, Singh S, Ahmed Y, Siddique S, Bilal S. Histopathological features of genital tract malignancies as seen in a tertiary health center in north-western Nigeria: A 10-year review. Ann Med Health Sci Res 2014; 4:213-217.
- [15] Sanni WO, Ocheke AN, Oyebode T, Jonah M, Nyango DD, Silas OA, et al. Pattern of Gynaecological Malignancies in Jos. Trop J Obstet Gynaecol 2013; 30 (1):97-102.
- [16] Abdullahi HI, Ayogu ME. Pattern and relative frequencies of gynecological malignancies at the University of Abuja Teaching Hospital, Abuja. Trop J Obstet Gynaecol 2020; 37:177-181.
- [17] Okunade KS, Okunola H, Okunowo AA, Anorlu RI. A five-year review of ovarian cancer at a tertiary institution in Lagos, South-West, Nigeria. Niger J Gen Pract 2016; 14:23-27.
- [18] Ibrahim HM, Ijaiya MA. Pattern of gynaecological malignancies at the University of Ilorin Teaching Hospital, Ilorin, Nigeria. J Obstet Gynaecol 2013; 33(2):194-196.
- [19] Umeobika JC, Ikeako LC, Ezenyeaku CT, Ezebialu UI, Ojiyi EC. Gynaecological Malignant Tumours at Imo State University Teaching Hospital Orlu Southeastern Nigeria. Afrimedic J 2018; 6 (1):52-58.
- [20] Osinachi IF, Adewole N, Isah AD, Abdullahi HI, Agida ET. Pattern of gynaecological malignancies in a Nigerian tertiary hospital. Afri J Med Health Sci 2020;19 (3):29-35.
- [21] Afroz S, Ara G, Sultana F. Pattern of Gynaecological Malignancies in a Tertiary Care Hospital. Open J Obstet Gynecol 2019; 9:449-457.
- [22] Sharma P, Pattanshetty SM. A study on risk factors of cervical cancer among patients attending a tertiary care hospital: A case-control study. Clin Epidemiol Global Health 2018; 6:83-87.
- [23] Garg S, Dasari P. Clinico-Pathological Profile of Women with Gynaecological Malignancies at a Tertiary Care Institute in South India. Indian J Gynecol Oncol 2020;18 (81):1-7.